PRKAG2-AS2: A Potential Drug Target and Biomarker (G644090)

Target Name: PRKAG2-AS2

NCBI ID: G644090

PRKAG2-AS2

Other Name(s): PRKAG2 antisense RNA 2 | LOC644090 variant X3 | Uncharacterized LOC644090, transcript variant X3

PRKAG2-AS2: A Potential Drug Target and Biomarker

Prkag2-AS2, also known as PRKAG2-AS2, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and function have made it an attractive target for researchers to investigate, and its potential as a drug has led to a surge of interest in the field of pharmacology.

The PRKAG2 gene is located on chromosome 19 and encodes for the protein Prkag2, which is a key regulator of the microtubules in cells. Microtubules are dynamic structures that play a crucial role in cell division, transport, and signaling. Prkag2 is known to be involved in the regulation of microtubule stability and dynamics, and its dysfunction has been implicated in various diseases, including cancer.

PRKAG2-AS2 is a short non-coding RNA molecule that has been shown to have unique structural features that give it a unique position in the regulation of microtubule dynamics. It has a length of 200 nucleotides and is composed of a single exon. The molecule has a 5' end that is attached to the Prkag2 gene, and a 3' end that is free to generate a stable RNA-protein complex with the protein Prkag2.

The 3' end of PRKAG2-AS2 contains a unique feature that is highly conserved in various species, known as a stem-loop region. This region has been shown to have a critical role in the regulation of microtubule stability and dynamics. The stem-loop region is composed of three distinct domains: an N-terminal domain, a middle domain, and a C-terminal domain.

The N-terminal domain is the first 20 nucleotides of the 3' end of PRKAG2-AS2. It contains a single nucleotide, G, which is known to have a stabilizing effect on the stem-loop region. The middle domain is the longest part of the 3' end of PRKAG2-AS2 and is composed of a series of alternating G and C nucleotides. The C-terminal domain is the last 10 nucleotides of the 3' end of PRKAG2-AS2 and is composed of a series of A, G, and C nucleotides.

The unique structure of PRKAG2-AS2 has led to a high degree of homology with other non-coding RNAs that are involved in the regulation of microtubule dynamics. This has led to the hypothesis that PRKAG2-AS2 may be a drug target for diseases that are characterized by dysfunction in microtubule regulation.

One of the key challenges in investigating the potential drug target of PRKAG2-AS2 is its expression and stability in various biological systems. While the molecule has been shown to be expressed in various tissues and cells, its levels and stability have not been fully characterized. studies have shown that PRKAG2-AS2 is expressed in various tissues, including brain, heart, and cancer. However, its levels and stability have not been fully determined.

Another challenge is the understanding of the mechanism of action of PRKAG2-AS2. While its function in the regulation of microtubule dynamics is well understood, its role in the regulation of other cellular processes is not yet fully understood. Further studies are needed to fully understand the mechanism of action of PRKAG2-AS2 and its potential as a drug target.

In conclusion, PRKAG2-AS2 is a non-coding RNA molecule that has unique structural features that give it a unique position in the regulation of microtubule dynamics. Its expression and stability have been

Protein Name: PRKAG2 Antisense RNA 2

The "PRKAG2-AS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRKAG2-AS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets